

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/I5C71EB0BF29EN.html>

Date: December 2022

Pages: 67

Price: US\$ 3,500.00 (Single User License)

ID: I5C71EB0BF29EN

Abstracts

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Interleukin-7 receptor is a protein found on the surface of cells. It is a receptor for interleukin-7. It acts as a receptor for thymic stromal lymphopoietin (TSLP). It plays an important role in T-cell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis.

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) pipeline Target constitutes close to 7 molecules. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 2 respectively. Report covers products from therapy areas Oncology, Infectious Disease, Dermatology, Gastrointestinal, Hematological Disorders, Immunology, Toxicology and Women's Health which include indications Coronavirus Disease 2019 (COVID-19), Non-Small Cell Lung Cancer, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Alopecia Areata, Anal Cancer, Bile Duct Cancer (Cholangiocarcinoma), Bladder Cancer, Breast Cancer, Cervical Intraepithelial Neoplasia (CIN), Colon Cancer, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Esophageal Cancer, Follicular Lymphoma, Gastric

Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Tumor, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, High-Grade Glioma, Human Papillomavirus Infections, Hypopharyngeal Cancer, Idiopathic CD4 Lymphocytopenia, Kaposi Sarcoma, Laryngeal Cancer, Lymphocytopenia, Malignant Mesothelioma, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional (Urothelial) Tract Cancer, Mycobacterium avium Infections, Oropharyngeal Cancer, Ovarian Cancer, Pancreatic Ductal Adenocarcinoma, Primary Sjogren's Syndrome, Progressive Multifocal Leukoencephalopathy, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Rectal Cancer, Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Sepsis, Sezary Syndrome, Small-Cell Lung Cancer, Squamous Cell Carcinoma, Triple-Negative Breast Cancer (TNBC) and Ulcerative Colitis.

The latest report Interleukin 7 Receptor Subunit Alpha - Drugs In Development, 2022, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R)

The report reviews Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's

most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Overview

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics

Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Therapeutics

Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Companies

Involved in Therapeutics Development

Allterum Therapeutics LLC

Genexine Inc

Medikine Inc

OSE Immunotherapeutics SA

RevImmune SAS

Zura Bio Ltd

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Drug Profiles

CYT-107 - Drug Profile

Product Description

Mechanism Of Action

History of Events

efineptakin alfa - Drug Profile

Product Description

Mechanism Of Action

History of Events

Iusvertikimab - Drug Profile

Product Description

Mechanism Of Action

History of Events

MDK-701 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Monoclonal Antibody to Antagonize IL7R for Acute Lymphocytic Leukemia - Drug Profile

Product Description

Mechanism Of Action

History of Events

OSE-703 - Drug Profile

Product Description

Mechanism Of Action

History of Events

ZB-168 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Dormant Products

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Discontinued

Products

Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) - Product

Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indications, 2022

Number of Products under Development by Indications, 2022 (Contd..1)

Number of Products under Development by Indications, 2022 (Contd..2)

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Allterum Therapeutics LLC, 2022

Pipeline by Genexine Inc, 2022

Pipeline by Medikine Inc, 2022

Pipeline by OSE Immunotherapeutics SA, 2022

Pipeline by RevImmune SAS, 2022

Pipeline by Zura Bio Ltd, 2022

Dormant Products, 2022

Dormant Products, 2022 (Contd..1)

Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Interleukin 7 Receptor Subunit Alpha (CDw127 or CD127 or IL7R) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/I5C71EB0BF29EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I5C71EB0BF29EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

